EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment

Monday O Ogese, Adam Lister, Liam Farrell, Joshua Gardner, Laila Kafu, Serat-E Ali, Andrew Gibson, Aimee Hillegas, Xiaoli Meng, Munir Pirmohamed, Geoffrey S Williams, Melanie Z Sakatis und 1 weitere

Toxicological Sciences · 2024

DOI: 10.1093/toxsci/kfad101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Monday O Ogese und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University o…. Hauptthemen laut MEDLINE: Hepatocytes, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BBSRC/GSK Industrial Partnership award, MRC Centre for Drug Safety Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vitro preclinical drug-induced liver injury (DILI) risk assessment relies largely on the use of hepatocytes to measure drug-specific changes in cell function or viability. Unfortunately, this does not provide indications toward the immunogenicity of drugs and/or the likelihood of idiosyncratic reactions in the clinic. This is because the molecular initiating event in immune DILI is an interaction of the drug-derived antigen with MHC proteins and the T-cell receptor. This study utilized immune cells from drug-naïve donors, recently established immune cell coculture systems and blinded compounds with and without DILI liabilities to determine whether these new methods offer an improvement over established assessment methods for the prediction of immune-mediated DILI. Ten blinded test compounds (6 with known DILI liabilities; 4 with lower DILI liabilities) and 5 training compounds, with known T-cell-mediated immune reactions in patients, were investigated. Naïve T-cells were activated with 4/5 of the training compounds (nitroso sulfamethoxazole, vancomycin, Bandrowski’s base, and carbamazepine) and clones derived from the priming assays were activated with drug in a dose-dependent manner. The test compounds with DILI liabilities did not stimulate T-cell proliferative responses during dendritic cell-T-cell coculture; however, CD4+ clones displaying reactivity were detected toward 2 compounds (ciprofloxacin and erythromycin) with known liabilities. Drug-responsive T-cells were not detected with the compounds with lower DILI liabilities. This study provides compelling evidence that assessment of intrinsic drug immunogenicity, although complex, can provide valuable information regarding immune liabilities of some compounds prior to clinical studies or when immune reactions are observed in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesChemical and Drug Induced Liver InjuryHumansCells, CulturedCoculture TechniquesRisk Assessment

Stichwörter der Autor:innen

T-lymphocytesadverse drug reactiondrug safety assessmentimmunogenicityliver

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutic, MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L693GE, UK.
  • Development Science, UCB Biopharma, Slough, Berkshire SL1 3WE, UK.
  • Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
  • Immunological Toxicology, In Vitro/In Vivo Translation, GSK, Collegeville, Pennsylvania, USA.
  • Immunological Toxicology, In Vitro/In Vivo Translation, GSK, David Jack Centre for R&D, Ware, Hertfordshire SG12 0DP, UK.
  • Global Investigative Safety, In Vitro/In Vivo Translation, GSK, David Jack Centre for R&D, Ware, Hertfordshire SG12 0DP, UK.

ORCID-Profile: Dean J Naisbitt

Förderung

  • BBSRC/GSK Industrial Partnership award
  • MRC Centre for Drug Safety Science

Zitieren

APA

Ogese, M. O., Lister, A., Farrell, L., Gardner, J., Kafu, L., Ali, S. E., Gibson, A., Hillegas, A., Meng, X., Pirmohamed, M., Williams, G. S., Sakatis, M. Z., & Naisbitt, D. J. (2024). A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfad101

Vancouver

Ogese MO, Lister A, Farrell L, Gardner J, Kafu L, Ali SE, et al. A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfad101

BibTeX
@article{Ogese2024,
  author = {Ogese, Monday O and Lister, Adam and Farrell, Liam and Gardner, Joshua and Kafu, Laila and Ali, Serat-E and Gibson, Andrew and Hillegas, Aimee and Meng, Xiaoli and Pirmohamed, Munir and Williams, Geoffrey S and Sakatis, Melanie Z and Naisbitt, Dean J},
  title = {A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment},
  journal = {Toxicological Sciences},
  year = {2024},
  doi = {10.1093/toxsci/kfad101}
}
Kostenlos starten →